Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitability and returns, stocks such as China Gas Holdings and Foxconn Interconnect Technology are expected to outperform its peers in the future. If a buoyant growth prospect is what you're after in your next investment, I've put together a list of high-growth stocks you may be interested in, based on the latest financial data from each company.
China Gas Holdings Limited ( SEHK:384 )
China Gas Holdings Limited, an investment holding company, operates as a natural gas services operator in the People's Republic of China. The company currently employs 41000 people and with the company's market capitalisation at HKD HK$138.87B, we can put it in the large-cap stocks category.
Extreme optimism for 384, as market analysts projected an outstanding earnings growth rate of 14.18% for the stock, supported by a double-digit sales growth of 45.96%. It appears that 384's profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 21.45%. 384 ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Considering 384 as a potential investment? I recommend researching its fundamentals here .
Foxconn Interconnect Technology Limited ( SEHK:6088 )
Foxconn Interconnect Technology Limited engages in the design, development, production, and sale of interconnect solutions and related products in Taiwan, Mainland China, the United States, Hong Kong, Singapore, and internationally. Established in 2013, and now run by Sung-Ching Lu, the company now has 47,700 employees and has a market cap of HKD HK$19.86B, putting it in the large-cap stocks category.
6088's projected future profit growth is a robust 22.11%, with an underlying 27.28% growth from its revenues expected over the upcoming years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn't artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. We see this bottom-line expansion directly benefiting shareholders, with expected positive return on equity of 13.20%. 6088 ticks the boxes for robust growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Should you add 6088 to your portfolio? Have a browse through its key fundamentals here .
Beijing Tong Ren Tang Chinese Medicine Company Limited ( SEHK:8138 )
Beijing Tong Ren Tang Chinese Medicine Company Limited, together with its subsidiaries, engages in the manufacture, retail, and wholesale of Chinese medicine and healthcare products to wholesalers and individuals. Established in 2004, and now led by CEO Yong Ling Ding, the company currently employs 809 people and with the stock's market cap sitting at HKD HK$10.88B, it comes under the large-cap stocks category.
An outstanding 14.24% earnings growth is forecasted for 8138, driven by an underlying sales growth of 32.14% over the next few years. An affirming signal is when net income increase is supported by top-line growth. Since net income isn't artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 23.86%. 8138's impressive outlook on all aspects makes it a worthy company to spend more time to understand. Should you add 8138 to your portfolio? Take a look at its other fundamentals here .
For more financially robust companies with high growth potential to enhance your portfolio, explore this interactive list of fast growing companies.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned.
